SMA Foundation

SMA Foundation

The mission of the SMA Foundation is to accelerate the development of a treatment for SMA, the number one genetic killer of infants and toddlers.

The SMA Foundation was established in 2003 by Loren Eng and Dinakar Singh, parents of a child with SMA. Today, the SMA Foundation is the leading funder of SMA research worldwide–over $100M has been spent on basic, translational, and clinical research. They have invested more than $30M on developing critical, validated research tools and other drug discovery assets. The mandate of the SMA Foundation is to ensure that all of the results of their research funding are made readily available to every SMA researcher with minimal cost and obligation.

SMA Foundation Goals:

To help accelerate the development of a treatment, the SMA Foundation is focused on four key strategies:

  1. Building alliances with academic and industry collaborators
  2. Developing in vitro and in vivo research tools for use by the research community and industry collaborators
  3. Funding novel preclinical and clinical research in the SMA field
  4. Educating legislators, governmental agencies, and the media about SMA research

888 Seventh Avenue, Suite 400
New York, NY
United States of America



Karen Chen Karen Chen

Karen S. Chen is the Chief Scientific Officer and the Chief Operating Officer of the Spinal Muscular Atrophy Foundation, responsible for overseeing the full range of our scientific and drug discovery programs, as well as managing the operations activities at the SMA Foundation.

Dr. Chen is a senior research scientist and manager with over 25 years of experience, including 15 years in industry, planning, directing, and conducting preclinical research. She has managed departments and groups working on a variety of projects for the discovery and development of novel therapeutics for neurological disorders.

More Info